Pathology · Malignant neoplasm of upper-outer quadrant of female breast

Biology and Pathology: Reading Your Report

At a Glance

A breast cancer pathology report explains the tumor type, grade, size, margins, lymph nodes, ER/PR and HER2 biomarkers, and sometimes genomic risk. These results help your oncology team estimate prognosis and choose treatments such as hormone therapy, targeted therapy, or chemotherapy.

Your pathology report is the “blueprint” of your diagnosis. It translates what the pathologist sees under a microscope into a set of data points that your oncology team uses to build your treatment plan. While the report can look like a wall of technical jargon, it essentially answers three questions: What kind of cells are these? How aggressive do they look? And what “fuel” do they use to grow? ^[1]^[2]

Keep in mind that some information (like your initial biomarkers) comes from your core biopsy, while definitive details (like final tumor size, exact margins, and the total number of involved lymph nodes) can only be confirmed after surgery.

The Two Main “Histologic” Types

The histologic type describes where the cancer began and how the cells behave.

Invasive Ductal Carcinoma (IDC-NST): This is the most common form, accounting for the vast majority of cases ^[3]. “NST” stands for “No Special Type,” meaning the cells look like typical breast cancer cells under the microscope.
Invasive Lobular Carcinoma (ILC): This type begins in the milk-producing glands (lobules). ILC is unique because the cells often lack a “glue” called E-cadherin, which normally holds cells together ^[3]^[4]. Without this glue, ILC cells tend to grow in single-file lines rather than forming a solid lump. This discohesive nature can make ILC harder to see on standard mammograms and may result in the cancer being larger than it appeared on initial scans ^[5]^[6].

Biomarkers: The “Subtype” of Your Cancer

Your doctors use key markers to help define your cancer’s subtype and predict which systemic treatments (like hormone therapy or targeted therapy) might work for you ^[7]^[8].

Estrogen Receptor (ER) and Progesterone Receptor (PR): These are “hormone-positive” markers. If a tumor has a high percentage of these receptors, it is likely to respond to endocrine (hormone-blocking) therapies. If an ER result is between 1% and 10%, it is considered ER-low positive; in these cases, the benefit of hormone therapy may be more limited ^[9].
HER2 (Human Epidermal Growth Factor Receptor 2): This is a protein on the surface of cells. A result of 3+ is positive, while 0 or 1+ is negative ^[10]. A result of 2+ is considered “equivocal” and requires a second, more detailed test called FISH or ISH to confirm the status ^[10].
Ki-67: This is a “proliferation marker” that measures how many cells are actively dividing. A higher percentage suggests a faster-growing tumor. While helpful for prognosis, doctors interpret it cautiously because testing methods can vary significantly between labs ^[11]^[12].

Grade vs. Stage: What’s the Difference?

It is common to confuse these two terms, but they measure different things.

Tumor Grade (The Nottingham Score): This is a pathology assessment of how abnormal the cells look compared to healthy cells. The pathologist evaluates tubule formation, nuclear pleomorphism (cell size/shape), and mitotic count (cell division) to generate a combined score from 3 to 9. This score translates into a Grade of 1, 2, or 3 ^[13]. Higher grades generally correlate with faster growth, but grade alone does not dictate your individual outcome ^[14].
Stage (The Reach): Staging evaluates how far the cancer has spread. Modern staging (AJCC 8th Edition) combines traditional Anatomic Stage (tumor Size, Nodes, Metastasis) with your grade and biomarkers to create a Prognostic Stage, providing a more accurate picture of your outlook ^[15]^[16].

Genomic Assays: Predicting Recurrence and Chemotherapy Benefit

If you have an early-stage, HR-positive, HER2-negative cancer, your doctor may order a genomic test like Oncotype DX or MammaPrint ^[17]. These tests look at the actual genes within the tumor.

Oncotype DX provides a Recurrence Score to help determine if chemotherapy will be beneficial.
MammaPrint reports genomic risk (Low vs. High Risk) ^[18].
The Age and Menopausal Factor: A “low” score does not universally mean chemotherapy has no value. For premenopausal women (especially those with 1–3 positive lymph nodes), chemotherapy or treatments that suppress the ovaries may still offer a significant benefit even if the score is intermediate or low ^[19]^[20].

Your Pathology Completeness Checklist

Ensure your report includes these essential elements:

[ ] Histologic Type (e.g., IDC, ILC, or Mixed) ^[1]
[ ] Tumor Size (measured in millimeters or centimeters) ^[1]
[ ] Histologic Grade (Nottingham score and Grade 1, 2, or 3) ^[13]
[ ] Margin Status (Is there a clear “buffer” of healthy tissue?) ^[21]
[ ] ER and PR Status (reported as a percentage) ^[9]
[ ] HER2 Status (0 to 3+ or FISH results) ^[10]
[ ] Lymph Node Status (Number of nodes examined vs. number involved) ^[22]
[ ] Lymphovascular Invasion (LVI) (Presence of cancer cells in small vessels) ^[1]

Common questions in this guide

What is the difference between invasive ductal and invasive lobular breast cancer?

Invasive ductal carcinoma starts in the breast ducts and is the most common type of invasive breast cancer. Invasive lobular carcinoma starts in the milk-producing lobules and often lacks a cell-adhesion protein called E-cadherin, so the cells may grow in single-file patterns and be harder to see on mammograms.

How are breast cancer grade and stage different?

Grade describes how abnormal the cancer cells look under a microscope and how quickly they may be growing; it is reported as Grade 1, 2, or 3. Stage describes the cancer’s size, lymph-node involvement, and spread, and a prognostic stage may also include the tumor’s biomarkers and grade.

What do ER, PR, and HER2 results mean on a pathology report?

ER and PR show whether the cancer cells have hormone receptors that may respond to hormone-blocking treatment. HER2 is reported from 0 to 3+: 3+ is positive, 0 or 1+ is negative, and 2+ is unclear and usually requires FISH or ISH testing.

What does ER-low positive mean?

ER-low positive means that 1% to 10% of the cancer cells have estrogen receptors. Hormone therapy may still be considered, but its benefit can be more limited than it is for cancers with higher receptor levels.

What does a HER2 2+ result mean?

A HER2 2+ result is considered equivocal, meaning the initial test does not clearly show whether the cancer is HER2-positive or HER2-negative. A follow-up FISH or ISH test is used to clarify the result.

What are Oncotype DX and MammaPrint used for in breast cancer?

For some early-stage, hormone-receptor-positive and HER2-negative cancers, these tests examine genes in the tumor to estimate recurrence risk and potential chemotherapy benefit. Oncotype DX gives a Recurrence Score, while MammaPrint reports low or high genomic risk; age, menopausal status, and lymph-node involvement also affect treatment decisions.

What information should be included in a breast cancer pathology report?

A complete report usually includes the cancer type, tumor size, grade, margin status, ER and PR percentages, HER2 results, lymph-node findings, and whether lymphovascular invasion is present. Some details come from a biopsy, while final size, margins, and lymph-node information may require surgery.

Curated prompts to bring to your next appointment.

1.What is the exact histologic type of my cancer, and does it show any 'mixed' features (like both ductal and lobular)?
2.My pathology report says my Nottingham score is [3-9], resulting in a Grade [1, 2, or 3]. What specifically about the cells led to that grade?
3.How does my 'prognostic stage' differ from my 'anatomic stage' based on the biomarkers?
4.Given my age, menopausal status, and receptor status, am I a candidate for an Oncotype DX or MammaPrint test?
5.If my HER2 result was 2+ (equivocal), has the 'reflex' FISH or ISH testing been completed yet?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

A pathology report identifies breast cancer type, size, grade, margins, lymph-node status, lymphovascular invasion, ER/PR status, and HER2 results.
Nottingham grade describes how the cancer cells look and behave under a microscope, while stage describes how far the cancer has spread and may incorporate biomarkers.
ER and PR results help guide hormone therapy, while HER2 results help identify potential targeted treatment; a HER2 2+ result requires FISH or ISH testing.
Oncotype DX and MammaPrint may help estimate recurrence risk and chemotherapy benefit in selected early-stage, hormone-receptor-positive, HER2-negative cancers.
Invasive lobular carcinoma may be harder to detect on mammograms because its cells can grow in single-file patterns, while invasive ductal carcinoma is the most common type.

References (22)

1
Correlation of tumor budding with a novel and other established prognostic parameters in patients with invasive breast carcinoma.
Borde ND, Thesiya YM, Mahajan MS, Bhale CP
Indian journal of pathology & microbiology 2025; (68(2)):310-316 doi:10.4103/ijpm.ijpm_920_23.
PMID: 39420848
2
A computable pathology report for precision medicine: extending an observables ontology unifying SNOMED CT and LOINC.
Campbell WS, Karlsson D, Vreeman DJ, et al.
Journal of the American Medical Informatics Association : JAMIA 2018; (25(3)):259-266 doi:10.1093/jamia/ocx097.
PMID: 29024958
3
E-Cadherin-Mediated Cell-Cell Adhesion and Invasive Lobular Breast Cancer.
Bullock E, Brunton VG
Advances in experimental medicine and biology 2025; (1464()):259-275 doi:10.1007/978-3-031-70875-6_14.
PMID: 39821030
4
Update in lobular breast lesions: Pathological diagnosis in the molecular era.
Bai L, Troxell ML
Human pathology 2025; (162()):105857 doi:10.1016/j.humpath.2025.105857.
PMID: 40562115
5
Lobular Breast Cancer: A Review.
Wilson N, Ironside A, Diana A, Oikonomidou O
Frontiers in oncology 2020; (10()):591399 doi:10.3389/fonc.2020.591399.
PMID: 33520704
6
Perivascular infiltration reflects subclinical lymph node metastasis in invasive lobular carcinoma.
Igawa A, Mizukami H, Kudoh K, et al.
Virchows Archiv : an international journal of pathology 2022; (481(4)):533-543 doi:10.1007/s00428-022-03391-8.
PMID: 35947202
7
The nature of triple-negative breast cancer classification and antitumoral strategies.
Kim S, Kim DH, Lee W, et al.
Genomics & informatics 2020; (18(4)):e35 doi:10.5808/GI.2020.18.4.e35.
PMID: 33412751
8
Breast cancer.
Harbeck N, Penault-Llorca F, Cortes J, et al.
Nature reviews. Disease primers 2019; (5(1)):66 doi:10.1038/s41572-019-0111-2.
PMID: 31548545
9
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
Allison KH, Hammond MEH, Dowsett M, et al.
Archives of pathology & laboratory medicine 2020; (144(5)):545-563 doi:10.5858/arpa.2019-0904-SA.
PMID: 31928354
10
Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer.
Jeong YS, Kang J, Lee J, et al.
Journal of pathology and translational medicine 2020; (54(1)):87-94 doi:10.4132/jptm.2019.10.14.
PMID: 31718121
11
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.
Finkelman BS, Zhang H, Hicks DG, Turner BM
Cancers 2023; (15(3)) doi:10.3390/cancers15030808.
PMID: 36765765
12
The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index.
Arima N, Nishimura R, Osako T, et al.
Journal of clinical pathology 2016; (69(3)):255-9 doi:10.1136/jclinpath-2015-203174.
PMID: 26420767
13
Exploring the Nottingham classification: assessing gene expression profiles in breast cancer patients and their association with outcomes.
Freitas AJA, Causin RL, Calfa S, et al.
Breast cancer research and treatment 2025; (212(2)):237-250 doi:10.1007/s10549-025-07718-2.
PMID: 40425927
14
The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution.
Tokunaga E, Ijichi H, Tajiri W, et al.
Breast cancer (Tokyo, Japan) 2020; (27(6)):1137-1146 doi:10.1007/s12282-020-01116-w.
PMID: 32472474
15
New and Important Changes in the TNM Staging System for Breast Cancer.
Hortobagyi GN, Edge SB, Giuliano A
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018; (38()):457-467 doi:10.1200/EDBK_201313.
PMID: 30231399
16
Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.
Weiss A, King TA, Hunt KK, Mittendorf EA
The Surgical clinics of North America 2018; (98(4)):687-702 doi:10.1016/j.suc.2018.03.005.
PMID: 30005768
17
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Andre F, Ismaila N, Allison KH, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.
PMID: 35439025
18
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Sparano JA, Gray RJ, Makower DF, et al.
The New England journal of medicine 2018; (379(2)):111-121 doi:10.1056/NEJMoa1804710.
PMID: 29860917
19
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
Kalinsky K, Barlow WE, Gralow JR, et al.
The New England journal of medicine 2021; (385(25)):2336-2347 doi:10.1056/NEJMoa2108873.
PMID: 34914339
20
Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review and economic evaluation.
Tappenden P, Cooper K, Hamilton J, et al.
Health technology assessment (Winchester, England) 2025; (29(49)):1-158 doi:10.3310/KGFD4040.
PMID: 41074908
21
Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE, Barnes NLP, Cramer A, et al.
Annals of oncology : official journal of the European Society for Medical Oncology 2015; (26(5)):1019-1025 doi:10.1093/annonc/mdv062.
PMID: 25678586
22
Micro- and macro-metastasis in the axillary lymph node: A review.
Naidoo K, Pinder SE
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2017; (15(2)):76-82 doi:10.1016/j.surge.2016.07.002.
PMID: 27498412

This page explains breast cancer pathology reports for informational purposes only and does not constitute medical advice. Your pathologist and oncology team should interpret your individual results and recommend care.

Get notified when new evidence is published on female breast upper-outer quadrant cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents